Diffusion Pharmaceuticals Inc

NASDAQ:DFFN  
0.54
-0.03 (-4.67%)
Products, Regulatory, Other Pre-Announcement

Diffusion Pharmaceuticals Reports Positive Trend In Oxygenation From TCOM Trial

Published: 06/30/2021 11:53 GMT
Diffusion Pharmaceuticals Inc (DFFN) - Diffusion Pharmaceuticals Reports Positive Trend in Oxygenation From Tcom Trial.
Diffusion Pharmaceuticals Inc - Intends to Initiate Clinical Studies in Identified Indications During First Half of 2022.
Diffusion Pharmaceuticals Inc - Anticipates Initiating and Completing Dlco and Altitude Trials in Second Half of 2021.
Diffusion Pharmaceuticals Inc - in Q4 of 2021, Company Expects to Announce Initial Hypoxia-related Indications.
Diffusion Pharmaceuticals Inc - Announced Topline Results From Company's Phase 1 Trial of Its Lead Product Candidate, Trans Sodium Crocetinate.